In order to explore the potential therapeutic drugs for NAFLD related to biomarkers, the compounds targeting the protein encoded by RPS3A were identified (Figure 6D, Supplementary Table 3). The gene discussed is RPS3A; the disease is metabolic dysfunction-associated steatotic liver disease.